uniQure N.V. Investors: Class Action Announcement from Kessler Topaz Meltzer & Check, LLP

A recent class action lawsuit has been initiated against uniQure N.V. by Kessler Topaz Meltzer & Check, LLP on behalf of investors who purchased or acquired uniQure ordinary shares between September 24, 2025, and October 31, 2025. This lawsuit, dubbed Scocco v. uniQure N.V., et al., Case No. 1:26-cv-01124, was lodged in the United States District Court for the Southern District of New York.

Investors who acquired uniQure ordinary shares during the specified Class Period have until April 13, 2026, to petition the Court to become the lead plaintiff for the class. If you experienced financial losses in relation to uniQure, reach out to Kessler Topaz Meltzer & Check, LLP for assistance through their website or contact attorney Jonathan Naji, Esq. via phone or email.

uniQure is a biotechnology firm focused on developing gene therapies for rare ailments such as Huntington’s disease (HD). Their lead drug candidate, AMT-130, is a groundbreaking gene therapy designed to decelerate the progression of HD, an inherited genetic disorder that affects nerve cells in the brain, resulting in movement and cognitive issues alongside psychiatric symptoms. Presently, there are no known cures or approved methods to slow down the disease progression. Despite some medications addressing specific HD symptoms, none effectively halt the disease’s progression towards a typically fatal outcome. AMT-130 is among the few drugs undergoing testing with the intention of slowing down the advancement of HD.

In March 2022, uniQure concluded patient enrollment for two ongoing multi-center, dose-escalating Phase I/II clinical trials for AMT-130 known as the Pivotal Phase I/II Study of AMT-130. The pivotal study received encouragement from Defendant Matthew Kapusta, the Company’s Chief Executive Officer, during interactions with investors in June and July 2025.

The legal actions against uniQure began when the Company disclosed the topline results of the Pivotal Study on September 24, 2025. Highlighting a “mean reduction from baseline in cerebrospinal neurofilament light protein” (CSF NfL) as a notable biomarker of neurodegeneration, uniQure claimed that AMT-130 displayed promising effectiveness in slowing neurodegeneration in HD patients. During an investor conference that same day, Defendant Kapusta expressed confidence in the study results, citing compelling evidence of AMT-130’s disease-modifying potential.

Moreover, Defendant Walid Abi-Saab, the Company’s Chief Medical Officer, emphasized the trial design discussions with the FDA and their agreement upon the acceptable clinical endpoints for accelerated approval. Through these statements, investors were led to believe in the likelihood of AMT-130 receiving accelerated approval from the FDA post-BLA submission in early 2026. Consequently, the market responded positively, with uniQure’s ordinary shares skyrocketing from $13.66 per share on September 23, 2025, to $47.50 per share the next day, marking a nearly 250% increase. By October 29, 2025, uniQure’s ordinary shares were trading above $70.00 per share.